Webcasted telephone conference: Immunovia reports historical breakthrough in early detection of pancreatic cancer in high risk groups
Tuesday, March 30 2021, at 16:30 CET
Presentations by: Patrik Dahlen, CEO, Thomas King, MD, PhD, Linda Mellby, PhD, Immunovia
Immunovia reports positive results of the blinded clinical validation of IMMray™ PanCan-d blood test for Stage I/II pancreatic cancers in familial/hereditary risk groups in USA – and improved test performance in detecting early stage pancreatic cancer in high risk symptomatic patients.
Immunovia’s IMMray™ PanCan-d Webinar Series
Thursday, December 17, 2020 at 15:00 CET
Webinar No. 3: IMMray™ PanCan-d Verification study and Clinical Use
Presentations by: Thomas King, MD, PhD, Linda Mellby, PhD, Laura Chirica, PhD, Immunovia
Moderator: Patrik Dahlen, CEO Immunovia
Immunovia interview with Prof. Stephen Pereira, Gastroenterologist and Hepatologist, BSc, PhD, FRCP, FRCPE, at the London Clinic (UCL), Principle Investigator for Immunovia´s PanSYM study in London, UK, in regard to the clinical utility of diagnostic tests in pancreatic cancer, December 8, 2020.
Wednesday, September 2, 2020 at 16:00 CET
Webinar No. 2: Commercial Test Model Study & Update on Launch Activities
Presenters: Linda Mellby, PhD; Laura Chirica, PhD and Thomas King, MD, PhD
Immunovia’s Virtual Investor Day, Tuesday, June 30, 2020
The online event features presentations by Immunovia’s Chairman, Carl Borrebaeck; CEO, Mats Grahn; Chief Commercial Officer, Laura Chirica; Senior VP Sales North America, Michael Pettigrew; and Dr Thomas King, Medical Director, followed by a Q&A session.
Monday, September 9, 2019 at 18:30 CET
Webinar No. 1: Differentiating Pancreatic Ductal Adenocarcinoma (PDAC) from individuals with symptoms suggestive of PDAC, including type II diabetes, with ROC AUC values above 0.95
Presenters: Linda Mellby, PhD and Thomas King, MD, PhD, Immunovia